Today’s Highlights- Prohost Biotech - Exclusive Biotech Research

Category: Today’s Highlights

Important and Encouraging News from Sutro Biopharma Inc

Sutro Biopharma Inc and Tasly Biopharmaceuticals Exclusive Licensing Agreement for STRO-002 In a press release from today, December 27, 2021, we learned that Sutro Biopharma Inc ( STRO ) and Tasly Biopharmaceuticals Co., Ltd. - a holding subsidiary of...

December 27, 2021

Interesting, Good News for Impel NeuroPharma and Migraine Sufferers

Impel NeuroPharma FDA Approval for TRUDHESA The U.S. Food and Drug Administration ( FDA ) approved Impel NeuroPharma ( IMPL ) product TRUDHESA (dihydroergotamine mesylate ( DHE )), previously known as INP104, a nasal spray for the treatment of acute...

September 3, 2021

The EMA Granted PRIME Designation to CRISPR Therapeutics’ and Vertex Pharmaceuticals' Product CTX001™ for Severe SCD

Crispr Therapeutics and Vertex Pharmaceuticals CTX001 Granted PRIME Designation by the EMA CRISPR Therapeutics ( CRSP ) and Vertex Pharmaceuticals ( VRTX ) announced that the European Medicines Agency ( EMA ) granted Priority Medicines ( PRIME ) designation to...

September 22, 2020

Why IVERIC bio Stock Rallied Today

IVERIC bio Stock Rally IVERIC bio ( ISEE ) stock rallied in early, premarket trading today as Stifel Nicolaus initiated a buy rating and a price target of $22. In premarket the stock was trading over $13.37, UP over $4...

September 10, 2021

We Are Back

We Are Back! Thanks to God. Hello to all our subscribers. Our sickness was unanticipated, making our year start in February rather than January. We will tackle the sickness later in another article. Now it is time to appreciate and...

February 1, 2022

Regenxbio and AbbVie: A Good Reason for RGNX to Soar Today

Regenxbio and AbbVie in the NEWS Regenxbio ( RGNX ) stock soared today. The Company, along with AbbVie ( ABBV ), announced a partnership to develop and commercialize RGX-314, a potential one-time gene therapy for the treatment of wet age-related...

September 13, 2021

Some Ideas About the Falling Stock Market Day

The Stock Market Today Before the end of 2021 we recognized that investors were not going to swallow what was reiterated about the strong economy. The fact was there were no criteria for a strong economy. Instead, the unparalleled inflation...

February 3, 2022

The U.S. FDA Accepted Intellia Therapeutics IND Application of NTLA-5001 for Acute Myeloid Leukemia

Intellia Therapeutics IND Application of NTLA-5001 for AML is Accepted by the US FDA NTLA-5001 is Intellia Therapeutics ( NTLA ) first wholly-owned ex vivo CRISPR genome editing candidate for the treatment of cancer. It is an autologous T cell...

September 16, 2021

Cassava Sciences, Moderna and Sorrento Therapeutics All Have News

News from Cassava Sciences, Moderna and Sorrento Therapeutics Cassava Sciences Cassava Sciences ( SAVA ) announced that clinical results of its Phase 2b study of sumifilam have been selected as a late-breaking oral presentation by the 13th international conference on...

September 30, 2020

Seagen Inc and Genmab Announce FDA Accelerated Approval for TIVDAK™ for Cervical Cancer

Seagen and Genmab Granted FDA Accelerated Approval for TIVDAK™ The U.S. FDA granted accelerated approval to Seagen Inc ( SGEN ) and Genmab A/S ( GMAB ) product TIVDAK™ (tisotumab vedotin-tftv), the first and only approved antibody-drug conjugate ( ADC )...

September 21, 2021

Search ProhostBiotech

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis

September 19, 2024

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024